Biogen Wins Vaccine Dispute With SB

23 April 1995

Biogen has announced that an arbitration panel has ruled in its favor in its dispute with SmithKline Beecham over the rate of royalties payable from US sales of SB's hepatitis B vaccine, Engerix B.

Biogen licensed its extensive hepatitis B patent portfolio to SB in 1988 for manufacturing and selling HBV vaccines. SB instituted the arbitration in 1993 in a bid to reduce the rate of royalty payments it was obliged to pay to Biogen. Since SB has continued to pay royalties at the disputed rate during the process, Biogen will not receive any extra payments as a result of the arbitration decision.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight